Zilovertamab vedotin

Advances in immunotherapy, including CAR T-cell therapy and bispecific antibodies, have significantly improved treatment for follicular lymphoma (FL), especially for relapsed patients. Axicabtagene ciloleucel (Yescarta) has shown durable remissions. DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report highlights 50+ companies and 55+ therapies in development. Key companies include Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and Johnson & Johnson Innovative Medicine. Promising therapies like Parsaclisib and TQ-B3525 are in various clinical phases. Recent developments include tafasitamab's Phase III success and collaborations for CAR-T therapies.

Merck announces new data for approved and investigational medicines across multiple hematologic malignancies to be presented at the ASH Annual Meeting, including zilovertamab vedotin and nemtabrutinib. Over 20 abstracts will showcase the company's progress in clinical research, with a focus on novel modalities and therapeutic targets.